Top

Clinical Reviews in Allergy & Immunology

Published in:

01-02-2022 | Tick

A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Immunologist

Authors: Katelyn H. Wong, Eugene D. Shapiro, Gary K. Soffer

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2022

Abstract

Lyme disease is an infection caused by Borrelia burgdorferi sensu lato, which is transmitted to humans through the bite of an infected Ixodes tick. The majority of patients recover without complications with antibiotic therapy. However, for a minority of patients, accompanying non-specific symptoms can persist for months following completion of therapy. The constellation of symptoms such as fatigue, cognitive dysfunction, and musculoskeletal pain that persist beyond 6 months and are associated with disability have been termed post-treatment Lyme disease syndrome (PTLDS), a subset of a broader term “chronic Lyme disease.” Chronic Lyme disease is a broad, vaguely defined term that is used to describe patients with non-specific symptoms that are attributed to a presumed persistent Borrelia burgdorferi infection in patients who may or may not have evidence of either previous or current Lyme disease. The diagnoses of chronic Lyme disease and of PTLDS have become increasingly relevant to the practice of immunologists due to referrals for consultation or for intravenous immunoglobulin (IVIG) treatment. This review aims to explore the relationship between chronic Lyme disease, post-treatment Lyme disease syndrome, and the immune system. Here, we review the current literature on (1) issues in conventional and alternative diagnostic testing for Lyme disease, (2) the hypothesis that B. burgdorferi infection can persist despite appropriate use of recommended antibiotics, (3) current theories regarding B. burgdorferi’s role in causing both immune dysregulation and protracted symptoms, and (4) the use of IVIG for the treatment of Lyme disease.

Wormser GP, Dattwyler RJ, Shapiro ED et al (2006) The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43:1089–1134. https://doi.org/10.1086/508667CrossRefPubMed

Shapiro ED, Dattwyler R, Nadelman RB, Wormser GP (2005) Response to meta-analysis of Lyme borreliosis symptoms. Int Epidemiol Assoc Int J Epidemiol 34:1437–1439. https://doi.org/10.1093/ije/dyi241CrossRef

Shapiro ED (2014) Clinical practice: Lyme disease. N Engl J Med 371. https://doi.org/10.1056/NEJMc1407264

Feder HM, Johnson BJB, O’Connell S et al (2007) A critical appraisal of chronic lyme disease. N Engl J Med 357:1422CrossRefPubMed

Dahlhamer J, Lucas J, Zelaya C et al (2018) Prevalence of chronic pain and high-impact chronic pain among adults—United States, 2016. MMWR Morb Mortal Wkly Rep 67:1001–1006. https://doi.org/10.15585/mmwr.mm6736a2

Ricci JA, Chee E, Lorandeau AL, Berger J (2007) Fatigue in the U.S. workforce: prevalence and implications for lost productive work time. J Occup Environ Med 49:1–10. https://doi.org/10.1097/01.jom.0000249782.60321.2aCrossRefPubMed

Blackwell D, Clarke TC (2013) QuickStats: percentage of adults who often felt very tired or exhausted in the past 3 months,* by sex and age group—national health interview survey, United States, 2010–2011†. MMWR Morb Mortal Wkly Rep 62:275PubMedCentral

Seltzer EG, Shapiro ED (1996) Misdiagnosis of Lyme disease: When not to order serologic tests. Pediatr Infect Dis J 15:762–763CrossRefPubMed

Tugwell P, Dennis DT, Weinstein A et al (1997) Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med 127:1109–1123. https://doi.org/10.7326/0003-4819-127-12-199712150-00011CrossRefPubMed

10.

Lipsett SC, Branda JA, Nigrovic LE (2019) Evaluation of the modified two-tiered testing method for diagnosis of Lyme disease in children. J Clin Microbiol 57. https://doi.org/10.1128/JCM.00547-19

11.

Branda JA, Strle K, Nigrovic LE et al (2017) Evaluation of modified 2-tiered serodiagnostic testing algorithms for early Lyme disease. Clin Infect Dis 64:1074–1080. https://doi.org/10.1093/cid/cix043CrossRefPubMedPubMedCentral

12.

Pegalajar-Jurado A, Schriefer ME, Welch RJ et al (2018) Evaluation of modified two-tiered testing algorithms for lyme disease laboratory diagnosis using well-characterized serum samples. J Clin Microbiol 56. https://doi.org/10.1128/JCM.01943-17

13.

Rebman AW, Crowder LA, Kirkpatrick A, Aucott JN (2014) Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients. Clin Rheumatol 34:585–589. https://doi.org/10.1007/s10067-014-2706-zCrossRefPubMed

14.

Moore A, Nelson C, Molins C et al (2016) Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of lyme disease, United States. Emerg Infect Dis 22:1169–1177. https://doi.org/10.3201/eid2207.151694CrossRefPubMedCentral

15.

Centers for Disease Control and Prevention (2013) Lyme disease diagnosis and testing. In: Centers Dis. Control Prev. http://www.cdc.gov/lyme/diagnosistesting/index.html. Accessed 15 May 2020

16.

Kalish RA, McHugh G, Granquist J et al (2001) Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10–20 years after active Lyme disease. Clin Infect Dis 33:780–785. https://doi.org/10.1086/322669CrossRefPubMed

17.

Qureshi M, New D, Zulqarni N, Nachman S (2002) Overdiagnosis and overtreatment of Lyme disease in children. Pediatr Infect Dis J 21:12–14. https://doi.org/10.1097/00006454-200201000-00003CrossRefPubMed

18.

Kobayashi T, Higgins Y, Samuels R et al (2019) Misdiagnosis of Lyme disease with unnecessary antimicrobial treatment characterizes patients referred to an academic infectious diseases. Clinic Open forum Infect Dis 6. https://doi.org/10.1093/OFID/OFZ299

19.

Reid M, Schoen R, Evans J et al (1998) The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 128:354–362. https://doi.org/10.7326/0003-4819-128-5-199803010-00003CrossRefPubMed

20.

Fallon BA, Pavlicova M, Coffino SW, Brenner C (2014) A comparison of Lyme disease serologic test results from 4 laboratories in patients with persistent symptoms after antibiotic treatment. https://doi.org/10.1093/cid/ciu703

21.

Centers for Disease Control and Prevention (2018) Laboratory tests that are not recommended. In: Centers Dis. Control Prev. https://www.cdc.gov/lyme/diagnosistesting/labtest/otherlab/index.html. Accessed 5 Jul 2020

22.

Schutzer SE, Body BA, Boyle J et al (2019) Direct diagnostic tests for Lyme disease. Clin Infect Dis. https://doi.org/10.1093/cid/ciy614CrossRefPubMedPubMedCentral

23.

Steere AC, Strle F, Wormser GP et al (2016) Lyme borreliosis. Nat Rev Dis Prim 2:16090. https://doi.org/10.1038/nrdp.2016.90CrossRefPubMed

24.

Jutras BL, Lochhead RB, Kloos ZA et al (2019) Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis. Proc Natl Acad Sci U S A 116:13498–13507. https://doi.org/10.1073/pnas.1904170116CrossRefPubMedPubMedCentral

25.

Lantos PM, Lantos PM, Rumbaugh J et al (2020) Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1215

26.

Steere AC (2020) Posttreatment Lyme disease syndromes: distinct pathogenesis caused by maladaptive host responses. J Clin Invest 130:2148–2151. https://doi.org/10.1172/JCI138062CrossRefPubMedPubMedCentral

27.

Chaconas G, Castellanos M, Verhey TB (2020) Changing of the guard: how the Lyme disease spirochete subverts the host immune response. J Biol Chem 295:301–313. https://doi.org/10.1074/jbc.REV119.008583CrossRefPubMed

28.

Tracy KE, Baumgarth N (2017) Borrelia burgdorferi manipulates innate and adaptive immunity to establish persistence in rodent reservoir hosts. Front Immunol 8:1–11. https://doi.org/10.3389/fimmu.2017.00116CrossRef

29.

Feng J, Li T, Yee R et al (2019) Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, post-treatment Lyme disease syndrome (PTLDS), and treatment failure. Discov Med 27:125–138PubMed

30.

Sharma B, Brown AV, Matluck NE et al (2015) Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother 59:4616–4624. https://doi.org/10.1128/AAC.00864-15CrossRefPubMedPubMedCentral

31.

Feng J, Shi W, Zhang S, Zhang Y (2015) Persister mechanisms in Borrelia burgdorferi: implications for improved intervention. Emerg. Microbes Infect 4:e51

32.

Caskey JR, Embers ME (2015) Persister development by Borrelia burgdorferi populations in vitro. Antimicrob Agents Chemother 59:6288–6295. https://doi.org/10.1128/AAC.00883-15CrossRefPubMedPubMedCentral

33.

Cabello FC, Godfrey HP, Bugrysheva JV, Newman SA (2017) Sleeper cells: the stringent response and persistence in the Borreliella (Borrelia) burgdorferi enzootic cycle. Environ. Microbiol. 19:3846–3862CrossRefPubMedPubMedCentral

34.

Hodzic E, Imai DM, Escobar E (2019) Generality of post-antimicrobial treatment persistence of borrelia burgdorferi strains N40 and B31 in genetically susceptible and resistant mouse strains. Infect Immun 87. https://doi.org/10.1128/IAI.00442-19

35.

Straubinger RK, Summers BA, Chang YF, Appel MJG (1997) Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 35:111–116. https://doi.org/10.1177/000992289703600514CrossRefPubMedPubMedCentral

36.

Embers ME, Barthold SW, Borda JT et al (2012) Persistence of borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One 7:1–12. https://doi.org/10.1371/journal.pone.0029914CrossRef

37.

Nadelman RB, Nowakowski J, Forseter G et al (1993) Failure to isolate borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: Report of a prospective study. Am J Med 94:583–588. https://doi.org/10.1016/0002-9343(93)90208-7CrossRefPubMed

38.

Baker PJ, Wormser GP (2017) The clinical relevance of studies on borrelia burgdorferi persisters. Am J Med. https://doi.org/10.1016/j.amjmed.2017.04.014CrossRefPubMed

39.

Hunfeld KP, Kraiczy P, Kekoukh E et al (2002) Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents - Possible implications for new therapeutic approaches to lyme disease. In: International Journal of Medical Microbiology. Elsevier GmbH, pp 125–137

40.

Iliopoulou BP, Guerau-de-Arellano M, Huber BT (2009) HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a mouse model of self-perpetuating arthritis. Arthritis Rheum 60:3831–3840. https://doi.org/10.1002/art.25005CrossRefPubMedPubMedCentral

41.

Steere AC, Klitz W, Drouin EE et al (2006) Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 203:961–971. https://doi.org/10.1084/jem.20052471CrossRefPubMedPubMedCentral

42.

Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA (2012) Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest 122:2652–2660. https://doi.org/10.1172/JCI58813CrossRefPubMedPubMedCentral

43.

Strle K, Sulka KB, Pianta A et al (2017) T-Helper 17 cell cytokine responses in Lyme disease correlate with borrelia burgdorferi antibodies during early infection and with autoantibodies late in the illness in patients with antibiotic-refractory Lyme arthritis. Clin Infect Dis 64:930–938. https://doi.org/10.1093/cid/cix002CrossRefPubMedPubMedCentral

44.

Divan A, Budd RC, Tobin RP, Newell-Rogers MK (2015) γδ T Cells and dendritic cells in refractory Lyme arthritis. J Leukoc Biol 97:653–663CrossRefPubMedPubMedCentral

45.

Lochhead RB, Arvikar SL, Aversa JM et al (2019) Robust interferon signature and suppressed tissue repair gene expression in synovial tissue from patients with postinfectious Borrelia burgdorferi-induced Lyme arthritis. Cell Microbiol 21. https://doi.org/10.1111/cmi.12954

46.

Vudattu NK, Strle K, Steere AC, Drouin EE (2013) Dysregulation of CD4+CD25high T cells in the synovial fluid of patients with antibiotic-refractory lyme arthritis. Arthritis Rheum 65:1643–1653. https://doi.org/10.1002/art.37910CrossRefPubMedPubMedCentral

47.

Shin JJ, Glickstein LJ, Steere AC (2007) High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum 56:1325–35. https://doi.org/10.1002/art.22441CrossRefPubMed

48.

Tory HO, Zurakowski D, Sundel RP (2010) Outcomes of children treated for lyme arthritis: Results of a large pediatric cohort. J Rheumatol 37:1049–1055. https://doi.org/10.3899/jrheum.090711CrossRefPubMed

49.

Steere AC, Angelis SM (2006) Therapy for lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 54:3079–3086CrossRefPubMed

50.

Aucott JN, Soloski MJ, Rebman AW et al (2016) CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome: a prospective clinical cohort study. Clin Vaccine Immunol 23:757–766. https://doi.org/10.1128/CVI.00071-16CrossRefPubMedPubMedCentral

51.

Strle K, Stupica D, Drouin EE et al (2013) Elevated levels of IL-23 in a subset of patients with post-Lyme disease symptoms following erythema migrans. https://doi.org/10.1093/cid/cit735

52.

Uhde M, Ajamian M, Li X et al (2016) Expression of C-reactive protein and serum amyloid A in early to late manifestations of Lyme disease. Clin Infect Dis. https://doi.org/10.1093/cid/ciw599CrossRefPubMedPubMedCentral

53.

Jacek E, Fallon BA, Chandra A et al (2013) Increased IFNα activity and differential antibody response in patients with a history of Lyme disease and persistent cognitive deficits. J Neuroimmunol 255:85–91CrossRefPubMed

54.

Klempner MS, Hu LT, Evans J et al (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345:85–92. https://doi.org/10.1056/NEJM200107123450202CrossRefPubMed

55.

Hickie I, Davenport T, Wakefield D et al (2006) Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. Br Med J 333:575–578. https://doi.org/10.1136/bmj.38933.585764.AECrossRef

56.

Batheja S, Nields JA, Landa A, Fallon BA (2013) Post-treatment lyme syndrome and central sensitization. J Neuropsychiatry Clin Neurosci 25:176–186CrossRefPubMed

57.

Wormser GP, Weitzner E, McKenna D et al (2015) Brief report: long-term assessment of fibromyalgia in patients with culture-confirmed Lyme disease. Arthritis Rheumatol 67:837–839. https://doi.org/10.1002/ART.38972CrossRefPubMed

58.

Eg S, Ma G, Ml C et al (2000) Long-term outcomes of persons with Lyme disease. JAMA 283:609–616. https://doi.org/10.1001/JAMA.283.5.609CrossRef

59.

Lantos PM (2015) Chronic Lyme disease. Infect Dis Clin North Am 29:325–340CrossRefPubMedPubMedCentral

60.

Krupp LB, Hyman LG, Grimson R et al (2003) Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60:1923–1930. https://doi.org/10.1212/01.WNL.0000071227.23769.9ECrossRefPubMed

61.

Kaplan RF, Trevino RP, Johnson GM et al (2003) Cognitive function in post-treatment Lyme disease: Do additional antibiotics help? Neurology 60:1916–1922. https://doi.org/10.1212/01.WNL.0000068030.26992.25CrossRefPubMed

62.

Fallon BA, Keilp JG, Corbera KM et al (2008) A randomized, placebo-controlled trial of repeated iv antibiotic therapy for lyme encephalopathy symbol. Neurology 70:992–1003. https://doi.org/10.1212/01.wnl.0000284604.61160.2dCrossRefPubMed

63.

Patel R, Grogg KL, Edwards WD et al (2000) Death from inappropriate therapy for Lyme disease. Clin Infect Dis 31:1107–1109. https://doi.org/10.1086/318138CrossRefPubMed

64.

Halperin JJ, Shapiro ED, Logigian E et al (2007) Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 69:91–102. https://doi.org/10.1212/01.wnl.0000265517.66976.28CrossRefPubMed

65.

Berende A, Hofstede HJMT, Vos FJ et al (2016) Randomized trial of longer-term therapy for symptoms attributed to lyme disease. N Engl J Med 374:1209–1220. https://doi.org/10.1056/NEJMoa1505425CrossRefPubMed

66.

Goodlet KJ, Fairman KA (2018) Adverse events associated with antibiotics and intravenous therapies for post-lyme disease syndrome in a commercially insured sample. Clin Infect Dis 67:1568–1574. https://doi.org/10.1093/cid/ciy329CrossRefPubMed

67.

Marzec NS, Nelson C, Waldron PR et al (2017) Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease—United States. MMWR Morb Mortal Wkly Rep 66:607–609. https://doi.org/10.15585/mmwr.mm6623a3

68.

Lantos PM, Shapiro ED, Auwaerter PG et al (2015) Unorthodox alternative therapies marketed to treat Lyme disease. https://doi.org/10.1093/cid/civ186CrossRef

69.

Crisp D, Ashby P (1996) Lyme radiculoneuritis treated with intravenous immunoglobulin. Neurology 46:1174–1175. https://doi.org/10.1212/WNL.46.4.1174CrossRefPubMed

70.

Celik T, Celik U, Kömür M et al (2016) Pediatric Lyme neuroborreliosis: different clinical presentations of the same agent; single center experience. Neuro Endocrinol Lett 37

71.

Rocha R, Lisboa L, Neves J et al (2012) Neuroborreliosis presenting as acute disseminated encephalomyelitis. Pediatr Emerg Care 28:1374–1376. https://doi.org/10.1097/PEC.0b013e318276c51dCrossRefPubMed

72.

Gannon M (2005) Alternative treatment gives patient a chance at a pain-free life. New Haven Regist. https://www.nhregister.com/news/article/Alternative-treatment-gives-patient-a-chance-at-a-11651283.php. Accessed 12 Jul 2020

73.

Fallon B, Marconi R (2009) 2009 10th Annual Scientific Conference: 34 Years, From Lyme, CT, Across the Nation Conference Summary. Lyme Dis Assoc. https://lymediseaseassociation.org/lda-conferences/summary-pages/2009-conf-summary/. Accessed 12 Jul 2020

74.

Stiehm ER (2013) Adverse effects of human immunoglobulin therapy. Transfus Med Rev 27:171–178. https://doi.org/10.1016/j.tmrv.2013.05.004CrossRefPubMed

Title: A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Immunologist
Authors: Katelyn H. Wong
Eugene D. Shapiro
Gary K. Soffer
Publication date: 01-02-2022
Publisher: Springer US
Keywords: Tick
Lyme Disease
Antibiotic
Tick
Lyme Arthritis
Fatigue
Published in: Clinical Reviews in Allergy & Immunology / Issue 1/2022
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-021-08906-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Are Physicochemical Properties Shaping the Allergenic Potency of Animal Allergens?

The Role of IgE in Upper and Lower Airway Disease: More Than Just Allergy!

Clinical Manifestations of Pediatric Food Allergy: a Contemporary Review

Different Phenotypes in Asthma: Clinical Findings and Experimental Animal Models

Are Physicochemical Properties Shaping the Allergenic Potency of Plant Allergens?

Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials